Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...

Grab plans to raise $1.25 billion via convertible bonds to fund buybacks and acquisitions, it said after issuing a fresh denial about a potential merger with Indonesian rival GoTo Gojek Tokopedia.

Grab plans to raise $1.25 billion via convertible bonds to fund buybacks and acquisitions, it said after issuing a fresh denial about a potential merger with Indonesian rival GoTo Gojek Tokopedia.

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated ...

Dr. Cissy Kityo Mutuluuza is a physician, epidemiologist, medical researcher, and the executive director of the Joint ...

Here is how Lam Research (LRCX) and Couchbase, Inc. (BASE) have performed compared to their sector so far this year.

Aribio Co. Ltd. signed a $600 million license deal with Acino International AG, an Arcera Life Sciences subsidiary, granting ...

Smoky air often has obvious short-term health effects like coughing and sore throat, but it can also have long-term impacts ...